Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome

Proteomics

Volumn 9, Issue 7, 2009, Pages 1982-1993

  Barderas, María G ^a,b   Tuñón, José ^a,c   Dardé, Verónica M ^a   De La Cuesta, Fernando ^a   Jiménez Nácher, José J ^d   Tarín, Nieves ^e   López Bescós, Lorenzo ^d   Egido, Jesús ^a,c   Vivanco, Fernando ^a,f  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e HOSPITAL DE MÓSTOLES   (Spain)

^f UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Atorvastatin; Cardiovascular; Monocytes; Two dimensional electrophoresis

Indexed keywords

ANTICOAGULANT AGENT; ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; CALGRANULIN B; CATHEPSIN D; ENDONUCLEASE; FICOLIN; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOCORTIN 1; LIPOCORTIN 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUCLEASE; PHOSPHOGLYCERATE KINASE; PROHIBITIN; PROTEIN DISULFIDE ISOMERASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRUVATE KINASE; STATHMIN; TRIACYLGLYCEROL; TRIOSEPHOSPHATE ISOMERASE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MALE; MASS SPECTROMETRY; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; TWO DIMENSIONAL ELECTROPHORESIS;

ACUTE CORONARY SYNDROME; AGED; ANTICHOLESTEREMIC AGENTS; CHI-SQUARE DISTRIBUTION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEAT-SHOCK PROTEINS; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; MONOCYTES; PYRROLES; STATISTICS, NONPARAMETRIC; TANDEM MASS SPECTROMETRY; THROMBOSIS;

AMBYSTOMA TIGRINUM STEBBENSI VIRUS;

EID: 65349128144     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200700583     Document Type: Article

References (57)

1. Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin study 4S. Lancet 1994, 344, 1383-1389.
2. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002, 360, 1623-1630.
3. Brown, B. G., Gotto, A. M., Impact of Management on Stabilization of Plaque and Reduction of Cardiovascular Events. in: Fuster, V., Topol, E. J., Nabel, E. G. (eds). Atherothrombosis and Coronary Artery Disease. Lippincott Wiliams & Wilkins, Philadelphia 2005, 153-164.
4. Blanco-Colio, L. M., Tuñón, J., Martín-Ventura, J. L., Egido, J., Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003, 63, 12-23.
5. Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G. et al., Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004, 291, 1071-1080.
6. Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J. et al., Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004, 350, 1495-1504.
7. Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N. et al., C- reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 2005, 352, 20-28.
8. Liuzzo, G., Vallejo, A. N., Kopecky, S. L., Frye, R. L. et al., Molecular fingerprint of interferon-gamma signaling in unstable angina. Circulation 2001, 103, 1509-1514.
9. Vivanco, F., Martin-Ventura, J. L., Duran, M. C., Barderas, M. G. et al., Quest for novel cardiovascular biomarkers by proteomic analysis. J. Proteome Res. 2005, 4, 1181-1191.
10. Torre-Amione, G., Immune activation in chronic heart failure. Am. J. Cardiol. 2005, 95, 3C-8C.
11. Gonzalez-Barderas, M., Gallego-Delgado, J., Mas, S., Durán, M. C. et al., Isolation of circulating human monocytes with high purity for proteomic analysis. Proteomics 2004, 4, 432- 437.
12. Anderson, L., Matheson, A., Steiner, S., Proteomics: Applications in basic and applied biology. Curr. Opin. Biotechnol. 2000, 11, 408-412.
13. Schevchenko, A., Wilm, M., Vorm, O., Mann, M., Mass spectrometric sequencing of proteins from silver stained polyacrylamide gels. Anal. Chem. 1996, 68, 850-858.
14. Martin-Ventura, J. L., Duran, M. C., Blanco-Colio, L. M., Meilhac, O. et al., Identification by differential proteomic approach of HSP-27 as a potential marker of atherosclerosis. Circulation 2004, 110, 2216-2219.
15. Barderas, M. G., Tuñon, J., Darde, V. M., de la Cuesta, F. et al., Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. J. Proteome Res. 2007, 6(2), 876-886.
16. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 2006, 355, 549-559.
17. Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T. et al., Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 2005, 352, 29-38.
18. Martin-Ventura, J. L., Blanco-Colio, L. M., Gomez-Hernandez, A., Muñoz-Garcia, B. et al., Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005, 36, 1796-1800.
19. 2 receptors in human carotid atherosclerotic plaques and monocytic cells. Potential implications for plaque stabilization. J. Cardiovasc. Pharmacol. 2006, 47, 60-69.
20. Yan, L., Ge, H., Li, H., Lieber, S. C. et al., Gender-specific proteomic alterations in glycolytic and mitochondrial pathways in aging monkey hearts. J. Mol. Cell. Cardiol. 2004, 37, 921-929.
21. Hsia, K. C., Li, C. L., Yuan, H. S., Structural and functional insight sugar-non specific nucleases in host defense. Curr. Opin. Struct. Biol. 2005, 15, 126-134.
22. Durrington, P. N., Mackness, B., Mackness, M. I., Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 473-480.
23. James, R. W., Levier, I., Righetti, A., Smoking is associated with reduced serum paraoxonase activity and concentration in patient with artery disease. Circulation 2000, 101, 2252- 2257.
24. Depre, C., Wang, L., Sui, X., Qiu, H. et al., H11 kinase prevents myocardial infarction by preemptive preconditioning of the heart. Circ. Res. 2006, 98, 280-288.
25. Fuhrman, B., Koren, L., Volkova, N., Keidar, S. et al., Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 2002, 164, 179-185.
26. Paragh, G., Torocsik, D., Seres, I., Harangi, M. et al., Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr. Med. Res. Opin. 2004, 20, 1321-1327.
27. Tomas, M., Senti, M., Garcia-Faria, F., Vila, J. et al., Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 2113-2119.
28. Zhu, J., Quyumi, A. A., Wu, H., Csako, G. et al., Increased serum levels of heat shock protein 70 are associated with low risk of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1055-1059.
29. Kol, A., Bourcier, T., Lichtman, A. H., Libby, P., Chlamydial and human heat shock protein 60 s activate human vascular endothelium, smooth muscle cells, and macrophages. J. Clin. Invest. 1999, 103, 571-577.
30. Uchiyama, T., Atsuta, H., Utsugi, T., Ohyama, Y. et al., Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis 2006, 188, 265-273
31. Kol, A., Sukhova, G. K., Lichtman, A. H., Libby, P., Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998, 98, 300- 307.
32. Xiao, Q., Mandal, K., Schett, G., Mayr, M. et al., Association of serum-soluble heat shock protein 60 with carotid atherosclerosis: Clinical significance determined in a follow-up study. Stroke 2005, 36, 2571-2576.
33. Gotoh, T., Terada, K., Oyadomari, S., Mori, M., Hsp70-DnaJ chaperone pair prevents nitric oxide- and CHOP-induced apoptosis by inhibiting translocation of Bax to mitochondria. Cell Death Differ. 2004, 11, 390-402.
34. Ghayour-Mobarhan, M., Lamb, D. J., Vaidya, N., Livingstone, C. et al., Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: A pilot study. Angiology 2005, 56, 61-68.
35. Roviezzo, F., Getting, S. J., Paul-Clark, M. J., Yona, S. et al., The annexin-1 knockout mouse: What it tells us about the inflammatory response. J. Physiol. Pharmacol. 2002, 53, 541-553.
36. Zouki, C., Ouellet, S., Filep, J. G., The anti-inflammatory peptides, antiflammins, regulate the expression of adhesion molecules on human leukocytes and prevent neutrophil adhesion to endothelial cells. FASEB J. 2000, 14, 572-580.
37. Hwang, J., Hodis, H. N., Hsiai, T. K., Asatryan, L., Sevanian, A., Role of Annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: The modulating effect of statins. Atherosclerosis 2006, 189, 76-82
38. Ishii, H., Yoshida, M., Hiraoka, M., Hajjar, K. A. et al., Recombinant Annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ. Res. 2001, 89, 1240-1245.
39. Hajjar, K. A., Krishnan, S., Annexin II: A mediator of the plasmin/plasminogen activator system. Trends Cardiovasc. Med. 1999, 9, 128-138.
40. Freedman, R. B., Hirst, T. R., Tuite, M. F., Protein disulphide isomerase: Building bridges in protein folding. Trends Biochem. Sci. 1994, 19, 331-336.
41. Higuchi, T., Watanabe, Y., Waga, I., Protein disulfide isomerase suppresses the transcriptional activity of NF-kB. Biochem. Biophys. Res. Commun. 2004, 318, 46-52.
42. Barnes, P. J., Karin, M., Nuclear factor-kappa B: A pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 1997, 336, 1066-1071.
43. Cominacini, L., Anselmi, M., Garbin, U., Pasini, A. F. et al., Enhanced plasma levels of oxidized low-density lipoprotein increase circulating nuclear factor-kappa B activation in patients with unstable angina. J. Am. Coll. Cardiol. 2005, 46, 799-806.
44. Kawabata, S., Tsuda, R., Molecular basis of non-self recognition by the horseshoe crab tachylectins. Biochim. Biophys. Acta 2002, 1572, 414-421.
45. Fujita, T., Evolution of the lectin-complement pathway and its role in innate immunity. Nat. Rev. Immunol. 2002, 2, 346- 353.
46. Yonezawa, S., Takahashi, T., Wang, X. J., Wong, R. N. et al., Structure at the proteolytic processing region of cathepsin D. J. Biol. Chem. 1998, 31, 16504-16511.
47. Hakala, J. K., Oksjoki, R., Laine, P., Du, H. et al., Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1430-1436.
48. Li, W., Dalen, H., Eaton, J. W., Yuan, X. M., Apoptotic death of inflammatory cells in human atheroma. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1124-1130.
49. Ramasamy, R., Yan, S. F., Schmidt, A. M., The RAGE axis and endothelial dysfunction: Maladaptive roles in the diabetic vasculature and beyond. Trends Cardiovasc. Med. 2005, 15, 237-243.
50. McCormick, M. M., Rahimi, F., Bobryshev, Y. V., Gaus, K. et al., S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J. Biol. Chem. 2005, 280, 41521-41529.
51. Tang, Y., Xu, H., Du, X., Lit, L. et al., Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: A micro array study. J. Cereb. Blood Flow Metab. 2006, 26, 1089-1102.
52. Iancu-Rubin, C., Atweh, G. F., p27(Kip1) and stathmin share the stage for the first time. Trends Cell Biol. 2005, 15, 346- 348.
53. Rubin, C. I., Atweh, G. F., The role of stathmin in the regulation of the cell cycle. J. Cell. Biochem. 2004, 93, 242-250.
54. Kinumi, T., Ogawa, Y., Kimata, J., Saito, Y. et al., Proteomic characterization of oxidative dysfunction in human umbilical vein endothelial cells (HUVEC) induced by exposure to oxidized LDL. Free Radic. Res. 2005, 39, 1335-1344.
55. Dickson, K. A., Haigis, M. C., Raines, R. T., Ribonuclease inhibitor: Structure and function. Prog. Nucleic Acid Res. Mol. Biol. 2005, 80, 349-374.
56. Nijtmans, L. G., de Jong, L., Artal Sanz, M., Coates, P. J. et al., Prohibitin acts as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J. 2000, 19, 2444-2451.
57. Mishra, S., Murphy, L. C., Nyomba, B. L., Murphy, L. J., Prohibitin: A potential target for new therapeutics. Trends Mol. Med. 2005, 11, 192-197.